Skip to content

Price / book at other companies

Eli Lilly logo
Eli LillyLLY
26.3×-20.7×
Arrowhead Research logo
Arrowhead ResearchARWR
14.3×+11.7×

Other financials

Income statement

See full
Revenue$311.3M+127%
Gross profit$43.5M
Operating income-$92.7M-16.9%
Net income-$94.4M-28.9%
EPS (diluted)-$3.25-24.5%

Balance sheet

See full
Cash & equivalents$232.2M+23.1%
Total debt$377.3M+187%
Total equity$543.5M-23.5%
Total assets$1.2B+23.1%

Cash flow

See full
Operating cash flow-$167.4M-88.4%
CapEx$3.8M
Free cash flow-$171.3M-92.7%

Valuation

See full
Market cap$11.66B+64.2%
Enterprise value$11.81B+67.5%
P/S10.3×-12.1×

Profitability

See full
Gross margin96.5%
Operating margin-27.7%-12.2pp
Net margin-27.3%-12.0pp
FCF margin-59.8%-29.6pp

Returns & leverage

See full
Return on equity-49.3%-0.8pp
Debt / equity0.7×+0.5×
Current ratio3.5×-2.4×

Where this comes from

Calculated from Madrigal Pharmaceuticals, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Madrigal Pharmaceuticals, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Madrigal Pharmaceuticals, Inc.'s price / book?
Madrigal Pharmaceuticals, Inc. (MDGL) reported price / book of 22.1× in Q1 2026.
How has Madrigal Pharmaceuticals, Inc.'s price / book changed year-over-year?
Madrigal Pharmaceuticals, Inc.'s price / book increased by 114.7% year-over-year, from 10.3× to 22.1×.
What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s price / book?
Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s price / book has grown at a 22.6% compound annual growth rate (CAGR), from 7.9× to 21.9×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.